Nasal cavity cancer

Summary

Nasal cavity cancer (MONDO:0001128) is a cancer and 4 clinical trials. Top therapeutic interventions include sacituzumab govitecan and camrelizumab. A subtype of respiratory system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nasal cavity cancer
Mondo ID	MONDO:0001128
DOID	DOID:10811
ICD-10-CM	C30.0
ICD-11	1078206702
NCIT	C4918
SNOMED CT	363422006
UMLS	C0728864
MedGen	152601
Anatomy (UBERON)	UBERON:0001707
Is cancer (heuristic)	yes

Also known as: cancer of nasal cavity · malignant nasal cavity neoplasm · malignant nasal cavity tumor · malignant nasal cavity tumour · malignant neoplasm of nasal cavities · malignant neoplasm of nasal cavity · malignant neoplasm of the nasal cavity · malignant tumor of nasal cavity · malignant tumor of the nasal cavity · malignant tumour of nasal cavity · malignant tumour of the nasal cavity · nasal cavity cancer

Disease family

This is a subtype of respiratory system cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › nasal cavity cancer

Related subtypes (8): tracheal cancer, bronchus cancer, larynx cancer, pharynx cancer, pleural cancer, lung cancer, SMARCA4-deficient sarcoma of thorax, paranasal sinus cancer

Subtypes (3): nasal cavity olfactory neuroblastoma, nasal cavity lymphoma, nasal cavity carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07063212	PHASE2	RECRUITING	A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
NCT05114707	PHASE2	UNKNOWN	Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses
NCT02012699	Not specified	RECRUITING	Integrated Cancer Repository for Cancer Research
NCT05614375	Not specified	RECRUITING	Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SACITUZUMAB GOVITECAN	4	1
CAMRELIZUMAB	3	1